Literature DB >> 11032025

Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain.

H Varma1, S E Conrad.   

Abstract

Proliferation of MCF-7 cells is estrogen dependent and antiestrogen sensitive. In the absence of estrogens or presence of antiestrogens MCF-7 cells arrest in the G1 phase of the cell cycle, and this arrest is associated with an accumulation of the active, hypophosphorylated form of the retinoblastoma protein (pRb). Because active pRb negatively regulates passage from G1 to S phase, this suggests that pRb is a crucial target of estrogen action, and that its inactivation might lead to antiestrogen resistance. We tested this hypothesis by expressing viral tumor antigens (T antigens), which bind and inactivate pRb, in MCF-7 cells, and determining the effects on cell proliferation in the presence of antiestrogens. The results of these experiments demonstrate that T antigen expression confers antiestrogen resistance to MCF-7 cells. Using a panel of mutant T antigens, we further demonstrate that the pRb-binding, but not the p53 binding domain is required to confer antiestrogen resistance. Thus, pRb is an important target of estrogen action, and its inactivation can contribute to the development of antiestrogen resistance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032025     DOI: 10.1038/sj.onc.1203827

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

Review 1.  Minireview: The Link Between ERα Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer.

Authors:  Stéphanie Légaré; Mark Basik
Journal:  Mol Endocrinol       Date:  2016-07-20

2.  Regulation of hormonal therapy resistance by cell cycle machinery.

Authors:  Binoj Chandrasekharan Nair; Ratna K Vadlamudi
Journal:  Gene Ther Mol Biol       Date:  2008-01-01

3.  Targeting the RB-pathway in cancer therapy.

Authors:  Erik S Knudsen; Jean Y J Wang
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

Review 4.  The other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axis.

Authors:  Xiaomin Lou; Ju Zhang; Siqi Liu; Ningzhi Xu; D Joshua Liao
Journal:  Cell Cycle       Date:  2014-05-05       Impact factor: 4.534

Review 5.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

Review 6.  The p53-estrogen receptor loop in cancer.

Authors:  C Berger; Y Qian; X Chen
Journal:  Curr Mol Med       Date:  2013-09       Impact factor: 2.222

7.  G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells.

Authors:  Akira Ichikawa; Jiro Ando; Koichi Suda
Journal:  Hum Cell       Date:  2008-05       Impact factor: 4.174

8.  Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples.

Authors:  Shinji Mizuarai; Takumitsu Machida; Tsutomu Kobayashi; Hideya Komatani; Hiraku Itadani; Hidehito Kotani
Journal:  Mol Cancer       Date:  2011-03-29       Impact factor: 27.401

9.  Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cells.

Authors:  Hemant Varma; Andrew J Skildum; Susan E Conrad
Journal:  PLoS One       Date:  2007-12-05       Impact factor: 3.240

Review 10.  RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy.

Authors:  Paola Indovina; Francesca Pentimalli; Nadia Casini; Immacolata Vocca; Antonio Giordano
Journal:  Oncotarget       Date:  2015-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.